文献速递肥胖与代谢综合征糖尿病

PPARγ激活、SMAD3抑制与肾上腺素受体激活协同诱导产热脂肪细胞改善啮齿类代谢异常

Synergistic activation of thermogenic adipocytes by a combination of PPARγ activation, SMAD3 inhibition and adrenergic receptor activation ameliorates metabolic abnormalities in rodents.
PubMed 文献 · Diabetologia · 2019-07-17

本研究在大鼠血管基质细胞及瘦型与饮食诱导肥胖(DIO)C57BL/6J小鼠中,探讨PPARγ激动剂罗格列酮、SMAD3抑制剂SIS3与肾上腺素受体激动剂去甲肾上腺素联合对白色脂肪「棕色化」的协同作用。结果显示三联处理协同诱导Ucp1、Fgf21和Cited1表达,DIO小鼠体脂减少、血清脂联素升高、糖脂耐受改善,提示联合调控PPARγ、SMAD与肾上腺素受体信号可作为治疗肥胖及相关疾病(包括2型糖尿病)的策略。

要点

  • PPARγ激动、SMAD3抑制与肾上腺素受体激活三联可协同诱导棕色脂肪生成。
  • DIO小鼠中三联给药第0至14天体重下降12.3%,并改善糖脂耐受。
  • 血清脂联素三联组均值65.56 μg/ml,对照组20.79 μg/ml(p < 0.05)。

核心结论

  • 联合调控PPARγ、SMAD和肾上腺素受体信号通路可协同诱导棕色脂肪生成,并可能成为治疗肥胖及相关疾病(包括2型糖尿病)的有效策略。

研究设计与样本

  • 体外使用大鼠血管基质细胞(stromal vascular fraction cells)筛选棕色化信号控制。
  • 体内使用瘦型与饮食诱导肥胖(DIO)C57BL/6J小鼠观察信号调控后的生理变化。

主要发现

  • 罗格列酮、SIS3与去甲肾上腺素联合协同诱导Ucp1、Fgf21和Cited1表达,触发棕色脂肪生成。
  • 三联对Ucp1的协同诱导受FOXO3负调控,机制为抑制PPARγ依赖的基因转录。
  • DIO小鼠给予罗格列酮、SIS3与选择性β3肾上腺素受体激动剂CL316,243后,体脂沉积减少(第0至14天体重下降12.3%),伴白色脂肪形态改变、线粒体生物合成增加及UCP1显著诱导。
  • 三联给药显著升高血清脂联素(均值65.56 μg/ml vs 对照20.79 μg/ml,p < 0.05),并改善糖脂耐受。

关键数值与推荐

  • DIO小鼠第0至14天体重下降12.3%。
  • 血清脂联素均值三联组65.56 μg/ml,对照组20.79 μg/ml,p < 0.05。

临床怎么用

  • 提示联合靶向PPARγ、SMAD3与肾上腺素受体信号可能增强白色脂肪棕色化,作为肥胖及2型糖尿病治疗的潜在策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: To treat obesity and related diseases, considerable effort has gone into developing strategies to convert white adipocytes into thermogenic brown-like adipocytes ('browning'). The purpose of this study was to identify the most efficient signal control for browning. METHODS: To identify the most efficient signal control for browning, we examined rat stromal vascular fraction cells. In addition, physiological changes consequent to signal control were examined in vivo using lean and diet-induced obese (DIO) C57BL/6J mice. RESULTS: Combined treatment with the peroxisome proliferator-activated receptor γ (PPARγ) agonist rosiglitazone, the SMAD3 inhibitor SIS3 and the adrenergic receptor agonist noradrenaline (norepinephrine) synergistically induced Ucp1, Fgf21 and Cited1 expression, triggering brown adipogenesis. Synergistic induction of Ucp1 by the three agents was negatively regulated by forkhead box O (FOXO)3 via the inhibition of PPARγ-dependent gene transcription. Moreover, the administration of rosiglitazone, SIS3 and the selective β3 adrenergic receptor agonist CL316,243 to DIO mice reduced the amount of body-fat deposits (body weight from day 0 to 14, 12.3% reduction), concomitant with morphological changes in white adipose tissue, an increase in mitochondrial biosynthesis and a marked induction of uncoupling protein 1 (UCP1). Furthermore, administration of the three agents significantly increased serum adiponectin levels (mean 65.56 μg/ml with the three agents vs 20.79 μg/ml in control mice, p < 0.05) and improved glucose and lipid tolerance. CONCLUSIONS/INTERPRETATION: These results suggest that the combined regulation of PPARγ, SMAD and the adrenergic receptor signalling pathway synergistically induces brown adipogenesis and may serve as an effective strategy to treat obesity and related diseases, including type 2 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Matsumoto T, Kiuchi S, Murase T, et al. Synergistic activation of thermogenic adipocytes by a combination of PPARγ activation, SMAD3 inhibition and adrenergic receptor activation ameliorates metabolic abnormalities in rodents. Diabetologia. 2019. PMID: 31317231. doi:10.1007/s00125-019-4938-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。